Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)

v3.22.1
CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
$ in Thousands
Series D Preferred Stock [Member]
Common Stock [Member]
At-the-Market Offering [Member]
Series D Preferred Stock [Member]
Common Stock [Member]
Settlement of Preferred Stock [Member]
Series D Preferred Stock [Member]
Common Stock [Member]
Cashless Exercise of Warrants [Member]
Series D Preferred Stock [Member]
Common Stock [Member]
Exercise of Options [Member]
Series D Preferred Stock [Member]
Common Stock [Member]
Exercise of Warrants [Member]
Series D Preferred Stock [Member]
Common Stock [Member]
Series E Preferred Stock [Member]
Additional Paid-in Capital [Member]
At-the-Market Offering [Member]
Series E Preferred Stock [Member]
Additional Paid-in Capital [Member]
Settlement of Preferred Stock [Member]
Series E Preferred Stock [Member]
Additional Paid-in Capital [Member]
Exercise of Options [Member]
Series E Preferred Stock [Member]
Additional Paid-in Capital [Member]
Exercise of Warrants [Member]
Series E Preferred Stock [Member]
Additional Paid-in Capital [Member]
Trek Therapeutics, PBC [Member]
Series E Preferred Stock [Member]
Additional Paid-in Capital [Member]
Series E Preferred Stock [Member]
Retained Earnings [Member]
Series C Preferred Stock [Member]
Settlement of Preferred Stock [Member]
Series C Preferred Stock [Member]
Noncontrolling Interest [Member]
Trek Therapeutics, PBC [Member]
Noncontrolling Interest [Member]
At-the-Market Offering [Member]
Exercise of Options [Member]
Exercise of Warrants [Member]
Trek Therapeutics, PBC [Member]
Total
Balance at Dec. 31, 2019           $ 23           $ 115,910 $ (104,787)       $ 515         $ 11,661
Balance (in Shares) at Dec. 31, 2019           23,323,087                                
Sale of common stock           $ 5 $ 2,228         25,210           $ 2,228       25,215
Sale of common stock (in Shares) 424,357         4,687,500                                
Sale of subsidiary shares to non-controlling interest                       7,124         3,468         $ 10,592
Sale of subsidiary shares to non-controlling interest (in Shares)                                           83,055
Common stock issued for services           $ 1           4,399                   $ 4,400
Common stock issued for services (in Shares)           679,555                                
Fair value of subsidiary shares issued to acquire research and development                     $ 2,439 1,051       $ 735 248       $ 3,174 1,299
Stock based compensation                       17,983         2,782         20,765
Stock based compensation (in Shares)           219,334                                
Preferred Stock dividend                       (14)                   (14)
Net loss                         (52,218)       (6,922)         $ (59,140)
Common stock issued upon conversion of preferred stock and accrued dividends               $ 70       110   $ 70 $ 110              
Common stock issued upon conversion of preferred stock and accrued dividends (in Shares)   15,516       29,334                                
Common stock issued upon exercise of warrants         $ 1         $ 2,089                   $ 2,090    
Common stock issued upon exercise of warrants (in Shares)     12,840   542,646                                  
Common stock issued in exchange for subsidiary shares                       24         (24)          
Common stock issued in exchange for subsidiary shares (in Shares)           83,055                 44,850              
Common stock issued upon exercise of options       $ 1         $ 2,721                   $ 2,722      
Common stock issued upon exercise of options (in Shares)       586,825   160,743                               1,203,223
Balance at Dec. 31, 2020           $ 31           181,344 (157,005)       802         $ 25,172
Balance (in Shares) at Dec. 31, 2020           30,764,792                               30,764,792
Sale of common stock             $ 1,300                     $ 1,300        
Sale of common stock (in Shares) 251,720                                          
Change in fair value of modified options                       313         8         $ 321
Sale of subsidiary shares to non-controlling interest           $ 3           9,001                   9,004
Sale of subsidiary shares to non-controlling interest (in Shares)           2,500,000                                
Common stock issued for services           $ 1           3,974                   3,975
Common stock issued for services (in Shares)           1,124,341                                
Stock based compensation           $ 1           5,176         348         5,525
Stock based compensation (in Shares)           916,952                                
Preferred Stock dividend                       (9)                   (9)
Net loss                         (31,917)       (939)         $ (32,856)
Common stock issued upon conversion of preferred stock and accrued dividends               $ 28           $ 28                
Common stock issued upon conversion of preferred stock and accrued dividends (in Shares)   9,375                                        
Common stock issued upon exercise of options (in Shares)                                     9,375     9,375
Balance at Dec. 31, 2021           $ 36           $ 201,127 $ (188,922)       $ 219         $ 12,460
Balance (in Shares) at Dec. 31, 2021           35,567,180                               35,567,180